Popular Articles
Burdock Root

Sol-Gel Anti-Acne Clinical Study Shows Significantly Improved Efficacy And Safety
Sol-Gel Technologies Ltd, a specialty pharmaceuticals company, announced today results from a comparative clinical study. The results demonstrate that the company"s two strength Anti-Acne kits achieved pronounced efficacy and markedly improved tolerability. The study will be presented at the 10th International Congress of Dermatology in Prague, May 20-23, 2009.
generic viagra online
Graphene's Versatility Promises New Applications
Since its discovery just a few years ago, graphene has climbed to the top of the heap of new super-materials poised to transform the electronics and nanotechnology landscape. As N.J. Tao, a researcher at the Biodesign Institute of Arizona State University explains, this two-dimensional honeycomb structure of carbon atoms is exceptionally strong and versatile. Its unusual properties make it ideal for applications that are pushing the existing limits of microchips, chemical sensing instruments, biosensors, ultracapacitance devices, flexible displays and other innovations.
News of the day
Washington Post Columnist Gerson Critical Of Justice Ginsburg's Comments On Abortion In NYT Magazine Interview
"There was a scandal this week" involving Supreme Court Justice Ruth Bader Ginsburg"s comments on abortion rights during an interview with the New York Times Magazine, according to Washington Post columnist Michael Gerson. In response to a question on access to abortion and restrictions on Medicaid coverage of the procedure, Ginsburg said, "Frankly I had thought that at the time Roe [v. Wade] was decided, there was concern about population growth and particularly growth in populations that we don"t want to have too many of. So that Roe was going to be then set up for Medicaid funding for abortion." According to Gerson, the "context surrounding this passage is a simplistic, pro-choice rant." He adds, "Abortion, in Ginsburg"s view, is an essential part of sexual equality, thus ending all ethical debate." Ginsburg in the interview also said, "There will never be a woman of means without choice anymore. That just seems to be so obvious." She added, "So we have a policy that affects only poor women, and it can never be otherwise, and I don"t know why this hasn"t been said more often."Gerson writes, "Given this context, can it be argued that Ginsburg -- referring to "populations that we don"t want to have too many of" -- was merely summarizing the views of others and describing the attitudes of the country when Roe v. Wade was decided?" He continues, "It can be argued -- but it is not bloody likely. Who, in Ginsburg"s statement, is the "we"? And who, in 1973, was arguing for the eugenic purposes of abortion?" According to Gerson, "It is more likely that Ginsburg is describing the attitude of some of her own social class -- that abortion is economically important to a "woman of means" and useful in reducing the number of social undesirables."Gerson writes, "The entire Ginsburg interview is a reminder of the risks of lifetime appointments to the Supreme Court." He continues, "Immune from criticism, surrounded by plump cushions of deference, the temperament of a justice can become exaggerated over time." He adds that her statements "would have been disqualifying" had they been made during her own confirmation hearing. "Now she doesn"t give a damn," Gerson says.He continues that Ginsburg"s "timing ... is instructive" because she made the remarks as Supreme Court nominee Sonia Sotomayor is "emphasizing her low-income and minority roots." According to Gerson, "It is estimated that the Hyde Amendment limiting Medicaid abortions has saved one million lives since its passage in 1976 -- some, no doubt, became criminals and some, perhaps, lawyers and judges." He concludes, "It is a defining question for modern liberalism: Are these men and women "populations that we don"t want to have too many of," or are they citizens worthy of justice and capable of contribution?" (Gerson, Washington Post, 7/17).
Public Health

Herceptin Improves Survival In Stomach Cancer Patients

A new study showed that the breast cancer drug Herceptin improved survival in patients with HER2-positive stomach cancer, an aggressive form of the disease. The study (called the ToGA study) was led by Eric Van Cutsem, a professor at the University Hospital Gasthuisberg, Leuven, Belgium and was presented at the annual meeting of the American Society of Clinical Oncology which is being held in Orlando Floriday from 29 May to 2 June. Patients diagnosed with advanced stomach (gastric) cancer generally do not have a good prognosis, the median survival time after initial diagnosis is about 10 months with current standard therapies. In an international phase III study sponsored by Roche, the drug company that markets Herceptin, Van Cutsem and colleagues found that adding Herceptin (trastuzumab) to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin) helped patients with HER2-positive stomach cancer live a median of 13.8 months compared with 11.1 months for those who had standard chemotherapy on its own. The trial enrolled 594 patients who tested positive for HER2 tumors from a group of about 3,800 patients with inoperable locally advanced, recurrent and/or metastatic stomach cancer. The study was done because Herceptin is known to be effective at targeting breast tumors that over-express HER2 and the investigators wanted to know if it might be effective in stomach cancers that also over-express HER2. Herceptin, a humanized antibody, is a targeted therapy that interferes with molecules that help HER2-positive tumors to grow. HER2 is a gene that expresses a protein called Human Epidermal growth factor Receptor 2 that is is responsible for making tumors aggressive by controlling the signalling pathways for cell growth and differentiation. The patients were randomized to one of two groups. One group received a fluoropyrimidine (Xeloda or intravenous 5-FU) and cisplatin every 3 weeks for 6 cycles, mostly in the form of a chemotherapy. The other group received Herceptin 6mg/kg every 3 weeks until progression, in additon to the fluoropyrimidine and cisplatin therapy for 6 cycles. The results also showed that: *Herceptin reduced the risk of death in patients with HER2-positive advanced and inoperable stomach cancer by 26 per cent compared to patients who were not given the drug. *Patients with tumors showing high levels of HER2 benefited even further from treatment with Herceptin: their survival was extended to an average of 16 months. In a prepared statment from Roche, Van Cutsem said there was a high "unmet medical need" in advanced forms of stomach cancer, and the study shows that using Herceptin as a targeted therapy contributes enormously to advancing therapy in this area. "To see this unprecedented survival benefit for patients with HER2-positive stomach cancer is enormously rewarding," said Van Cutsem. Every year more than 1 million people find out they have stomach cancer, which is the second most common cause of cancer-related death worldwide. Symptoms don"t show in the early stages, making the disease a difficult one to diagnose soon enough to allow early treatment that would improve prognosis. HER2-positive stomach cancer accounts for about 22 per cent of stomach cancers: this is the same in Europe and Asia where the disease is most prevalent. CEO of Roche"s Pharmaceuticals Division, William M Burns, said that Herceptin had been an enormous benefit to women with HER2-positive breast cancer, and the company was "extremely pleased to see its impressive benefit extending to patients with stomach cancer". "The targeted therapy Herceptin will become the new standard of care and we can make an important contribution in helping these patients live longer," he added. Herceptin is sold in the US Genentech, in Japan by Chugai and internationally by Roche. Worldwide, nearly 600,000 patients with HER2-positive breast cancer have been treated with Herceptin since 1998. Main Roche. Written by: Catharine Paddock, PhD Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):